Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy

Francia, Raffaele Di; Monaco, Angela De; Saggese, Mariangela; Iaccarino, Giancarla; Crisci, Stefania; Frigeri, Ferdinando; Filippi, Rosaria De; Berretta, Massimiliano; Pinto, Antonio

doi:10.2174/1568009617666170208162841

Cited by 50 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Uzun yıllar boyunca geliştirilen tedaviler tümör ilerlemesinin, nüksünün ve mortalitenin azaltılması amacı ile geliştirilmiş sitotoksik kemoterapiye dayanmaktadır. Bu kemoterapiler, tüm mitotik hücreleri hedef aldığından kanser hücrelerinin yanında bazı normal doku hücrelerine de zarar verebilmektedir (3). Son yıllarda kanser vakalarındaki artış ve mevcut kemoterapilerin yan etkileri, normal hücreler üzerinde zararlı etkisi olmayan, sadece kanser hücrelerinde toksik etki gösteren yeni ilaçların araştırılmasına yol açmıştır (4).…”

Section: öZunclassified

Betülinik Asit ve Antikanser Etkileri

Ataş¹,

Ergen²

2020

Experimed

View full text Add to dashboard Cite

In recent years, interest in naturally occurring compounds in plants has been increasing. Due to the benefits of these compounds, various studies have been carried out for their therapeutic use in cancer treatment as well as in daily use. These studies have aimed to develop chemotherapeutics that are natural and can stimulate apoptosis due to the side effects of chemotherapeutics used in current cancer treatments. One of these compounds, betulinic acid, is lupane-type pentacyclic triterpenoid, a secondary metabolite found in the bark of various trees. Betulinic acid has strong anticancer properties as well as antiviral and anti-inflammatory effects. It performs its anticancer functions by promoting the mitochondrial apoptosis, regulating cell cycle and angiogenesis, and activating or deactivating many pathways which are important for cancer development. Molecules that directly affect mitochondria such as betulinic acid, hold great promise in preventing drug resistance that may occur in the treatment process. In addition, the fact that betulinic acid directly affects cancer cells and has no toxic effect on healthy cells makes it a potential anticancer molecule in developing chemotherapy strategies. This review aims to discuss the structural and biological properties of betulinic acid and the anticancer effects in various cancer types.

show abstract

Section: öZunclassified

Betülinik Asit ve Antikanser Etkileri

Ataş¹,

Ergen²

2020

Experimed

View full text Add to dashboard Cite

show abstract

“…Fusing this important information and novel network-based models, researchers may find some valuable drug discovery strategies. In addition, computational models could be applied to predict personalized drug targets, drug effects and resistances for cancer treatment, and infer personalized cancer risk for healthy individuals [89,90]. Therefore, performing personalized medicine based on DTI identification may be a topic of further research.…”

Section: Conclusion and Further Researchmentioning

confidence: 99%

Revealing Drug-Target Interactions with Computational Models and Algorithms

Zhou

Yang

et al. 2019

Molecules

View full text Add to dashboard Cite

Background: Identifying possible drug-target interactions (DTIs) has become an important task in drug research and development. Although high-throughput screening is becoming available, experimental methods narrow down the validation space because of extremely high cost, low success rate, and time consumption. Therefore, various computational models have been exploited to infer DTI candidates. Methods: We introduced relevant databases and packages, mainly provided a comprehensive review of computational models for DTI identification, including network-based algorithms and machine learning-based methods. Specially, machine learning-based methods mainly include bipartite local model, matrix factorization, regularized least squares, and deep learning. Results: Although computational methods have obtained significant improvement in the process of DTI prediction, these models have their limitations. We discussed potential avenues for boosting DTI prediction accuracy as well as further directions.

show abstract

“…The benefits of combining N/DSs with AIs, antiblastic chemotherapy, or other targeted agents are being tested in preclinical and clinical trials of several malignancies [77]. However, choosing the most effective combinations requires a better knowledge of the mechanisms by which the antiangiogenetic effects are achieved or the new strategies reach their molecular targets [78]. Recent advances provide exceptional opportunities to identify the genetic profile of those patients who will benefit from targeted therapy and to exclude those who are at high risk of severe toxicity [79,80].…”

Section: Conclusion and Future Directionmentioning

confidence: 99%

Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors

Francia

Berretta

Benincasa

et al. 2019

Cells

Self Cite

View full text Add to dashboard Cite

Background: Angiogenesis inhibitors (AIs) have become established as an effective cancer treatment. Whereas their interactions with antineoplastic drugs have extensively been investigated, little is known of the effect of their co-administration with nutraceuticals/dietary supplements (N/DSs), which are often self-prescribed. N/DSs comprise a wide range of products such as herbs, nutrients, vitamins, minerals, and probiotics. Assessment of their interactions with cancer drugs, particularly AIs, is hampered by the difficulty of gauging the amount of active substances patients actually take. Moreover, there is no agreement on which approach should be used to determine which N/DSs are most likely to influence AI treatment efficacy. We present a comprehensive review of the metabolic routes of the major AIs and their possible interactions with N/DSs. Methods: The PubMed and Cochrane databases were searched for papers describing the metabolic routes of the main AIs and N/DSs. Results: Data from the 133 studies thus identified were used to compile a diagnostic table reporting known and expected AI-N/DS interactions based on their metabolization pathways. AIs and N/DSs sharing the cytochrome P450 pathway are at risk of negative interactions. Conclusions: Recent advances in pharmacogenetics offer exceptional opportunities to identify prognostic and predictive markers to enhance the efficacy of individualized AI treatments. The table provides a guide to genotyping patients who are due to receive AIs and is a promising tool to prevent occult AI-N/DS interactions in poor metabolizers. N/DS use by cancer patients receiving AIs is a topical problem requiring urgent attention from the scientific community.

show abstract

Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy

Cited by 50 publications

References 0 publications

Betülinik Asit ve Antikanser Etkileri

Betülinik Asit ve Antikanser Etkileri

Revealing Drug-Target Interactions with Computational Models and Algorithms

Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors

Contact Info

Product

Resources

About